Who
Brian J.G. Pereira
Director
Company insider
Files Form 4 as: Director, ProKidney; Director, KalVista Pharmaceuticals; Executive Chairman, Abeona Therapeutics; Director, Biodel; President and CEO, Amag Pharmaceuticals.
In numbers
- Trades disclosed
- 167
- Buys
- 1
- Sells
- 25
- Bought
- $465K
- Sold
- $22.0M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 7 Feb 2006
- Last trade
- 20 Aug 2026
- Last filed
- 20 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Aug 2026filed 20 Aug 2026 | PROK ProKidneyBiotechnology | SEC FORM 4 Sold | $317K222,948 at $1.42 | filing |
| 20 Aug 2026filed 20 Aug 2026 | PROK ProKidneyBiotechnology | SEC FORM 4 Sold | $38K27,052 at $1.42 | filing |
| 20 Aug 2026filed 20 Aug 2026 | PROK ProKidneyBiotechnology | SEC FORM 4 Sold | $317K222,948 at $1.42 | filing |
| 20 Aug 2026filed 20 Aug 2026 | PROK ProKidneyBiotechnology | SEC FORM 4 Sold | $38K27,052 at $1.42 | filing |
| 19 Aug 2026filed 20 Aug 2026 | PROK ProKidneyBiotechnology | SEC FORM 4 Sold | $321K222,949 at $1.44 | filing |
| 19 Aug 2026filed 20 Aug 2026 | PROK ProKidneyBiotechnology | SEC FORM 4 Sold | $39K27,051 at $1.44 | filing |
| 19 Aug 2026filed 20 Aug 2026 | PROK ProKidneyBiotechnology | SEC FORM 4 Sold | $321K222,949 at $1.44 | filing |
| 19 Aug 2026filed 20 Aug 2026 | PROK ProKidneyBiotechnology | SEC FORM 4 Sold | $39K27,051 at $1.44 | filing |
| 18 Aug 2026filed 20 Aug 2026 | PROK ProKidneyBiotechnology | SEC FORM 4 Sold | $314K229,338 at $1.37 | filing |
| 18 Aug 2026filed 20 Aug 2026 | PROK ProKidneyBiotechnology | SEC FORM 4 Sold | $38K27,826 at $1.37 | filing |
| 18 Aug 2026filed 20 Aug 2026 | PROK ProKidneyBiotechnology | SEC FORM 4 Sold | $314K229,338 at $1.37 | filing |
| 18 Aug 2026filed 20 Aug 2026 | PROK ProKidneyBiotechnology | SEC FORM 4 Sold | $38K27,826 at $1.37 | filing |
| 4 Aug 2026filed 6 Aug 2026 | PROK ProKidneyBiotechnology | SEC FORM 4 Code C | —81,929 at $0.00 | filing |
| 4 Aug 2026filed 6 Aug 2026 | PROK ProKidneyBiotechnology | SEC FORM 4 Code C | —675,235 at $0.00 | filing |
| 4 Aug 2026filed 6 Aug 2026 | PROK ProKidneyoption or derivative · Biotechnology | SEC FORM 4 Code C | —81,929 at $0.00 | filing |
| 4 Aug 2026filed 6 Aug 2026 | PROK ProKidneyoption or derivative · Biotechnology | SEC FORM 4 Code C | —81,929 at $0.00 | filing |
| 4 Aug 2026filed 6 Aug 2026 | PROK ProKidneyoption or derivative · Biotechnology | SEC FORM 4 Code C | —81,929 at $0.00 | filing |
| 4 Aug 2026filed 6 Aug 2026 | PROK ProKidneyoption or derivative · Biotechnology | SEC FORM 4 Code C | —675,235 at $0.00 | filing |
| 4 Aug 2026filed 6 Aug 2026 | PROK ProKidneyoption or derivative · Biotechnology | SEC FORM 4 Code C | —675,235 at $0.00 | filing |
| 4 Aug 2026filed 6 Aug 2026 | PROK ProKidneyoption or derivative · Biotechnology | SEC FORM 4 Code C | —81,929 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.